alexa Abstract | Low-dose Metronomic Capecitabine (Xeloda) for Treatment of Metastatic Gastrointestinal Cancer: A Clinical Study

Archives in Cancer Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


Background: Metastatic gastrointestinal cancer (GI-cancer) is often a chronic disease where the treatment intention often is palliative. For such patients, it is important to offer treatments that can prevent tumor progression without reducing quality of life more than necessary. Metronomic chemotherapy involves continuous administration of cytostatic drugs at low doses without longer drugfree intervals. Capecitabine (Xeloda) is a prodrug, given in a tablet formulation, that is selectively converted to 5-Fluorouracil at the tumor sites. In this study, we aimed to explore the efficacy and tolerability of metronomic Xeloda.

Methods: Patients (n = 87) diagnosed with a primary metastatic or recurrent disease were included and retrospectively analyzed. Clinical data were obtained from patient journals. All patients had been treated with metronomic Xeloda (500 mg × 2). Primary endpoints were to investigate the two-year overall survival (OS) and the best response. Best response was evaluated by radiological and clinical examination. Standard RECIST criteria were used. Survival analysis was performed using the Kaplan-Meier method.

Results: Regress stable disease and progress were seen in 13% (n = 11), 38% (n = 33) and 47% (n = 41) of the cases respectively. The two-year OS for the cohort was 56% and median OS was 26 months. The treatment was well tolerable and all reported side effects (n = 21) were of toxicity grade I or II.

Conclusions: Our data show that metronomic Xeloda may offer a therapeutic alternative for highly motivated patients in a good general condition when evidence-based regimens are not considered suitable or have failed.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Dennis Genfors and Maria Albertsson


Gastrointestinal cancer, Metronomic chemotherapy, Capecitabine, Response, Quality of life, Cancer and Metastasis, Oncology Research

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version